Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 4, 2021
- Accepted in final form June 16, 2021
- First Published August 12, 2021.
Author Disclosures
- Belinda Carrión, MD, PhD (bca{at}tec.mx),
- Yawei Liu, MD, PhD (yawei.liu{at}bric.ku.dk),
- Mahdieh Hadi, PhD (mahdieh.hadi{at}bric.ku.dk),
- Jon Lundstrom, MSc (jon.lundstrom{at}bric.ku.dk),
- Jeppe Romme Christensen, MD, PhD (jeppe.romme.christensen{at}regionh.dk),
- Cecilie Ammitzbøll, MD, PhD (cecilie.ammitzboell{at}regionh.dk),
- Morten Hanefeld Dziegiel, MD, PhD (morten.dziegiel{at}regionh.dk),
- Per Soelberg Sørensen, MD (per.soelberg.soerensen{at}regionh.dk),
- Manuel Comabella, MD, PhD (manuel.comabella{at}vhir.org),
- Xavier Montalban, MD, PhD (xavier.montalban{at}cem-cat.org),
- Finn Sellebjerg, MD, PhD (sellebjerg{at}dadlnet.dk) and
- Shohreh Issazadeh-Navikas, PhD
- Belinda Carrión, MD, PhD (bca{at}tec.mx),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yawei Liu, MD, PhD (yawei.liu{at}bric.ku.dk),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mahdieh Hadi, PhD (mahdieh.hadi{at}bric.ku.dk),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
MS International Federation-McDonald Fellowship to Mahdieh Hadi for two years. 2015
NONE
NONE
NONE
NONE
NONE
NONE
- Jon Lundstrom, MSc (jon.lundstrom{at}bric.ku.dk),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeppe Romme Christensen, MD, PhD (jeppe.romme.christensen{at}regionh.dk),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cecilie Ammitzbøll, MD, PhD (cecilie.ammitzboell{at}regionh.dk),
None
NONE
(1) Genzyme, travel support
NONE
A patent pending for a stoma care invention. It is a device for collection of stoma output and it is a total different topic than this manuscript covers.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Morten Hanefeld Dziegiel, MD, PhD (morten.dziegiel{at}regionh.dk),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Per Soelberg Sørensen, MD (per.soelberg.soerensen{at}regionh.dk),
(1) Merck KGaA (2) Teva(3) Novartis
NONE
(1) Merck KGaA: Travel and speaker honoraria for meetings, honoraria for serving on Independent Data Monitoring Committee(2) TEVA: Travel and speaker honoraria for meeting, educational activities.(5) Novartis: Travel and speaker honoraria for meeting, honoraria for serving on Independent Data Monitoring Committee
(1) Therapeutic Advances in Neurological Diseases: Memberof External Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Manuel Comabella, MD, PhD (manuel.comabella{at}vhir.org),
NONE
NONE
I received speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Genzyme, and Novartis.
(1)Journal of Neuroimmunology, Editorial advisory board, (2009-present) (2)Multiple Sclerosis Journal, Editorial advisory board, (2013-present) (3)PLoS ONE, Editorial advisory board, (2014-2016)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Red Española de Esclerosis Múltiple (REEM) 2014 - present. (2) Fondo de Investigación Sanitaria (FIS, Instituto de Salud Carlos III (2014 - present)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Montalban, MD, PhD (xavier.montalban{at}cem-cat.org),
(1) Actelion, (2) Alexion, (3) Biogen, (4) Bristol-Myers Squibb/Celgene, (5) EMD Serono, (6) Genzyme, (7) Hoffmann-La Roche, (8) Immunic, (9) Janssen Pharmaceuticals, (10) Medday, (11) Merck, (12) Mylan, (13) Nervgen, (14) Novartis, (15) Sanofi-Genzyme, (16) Teva Pharmaceutical, (17) TG Therapeutics
NONE
Travel to scientific meetings: (1) Actelion, (2) Alexion, (3) Biogen, (4) Bristol- Myers Squibb/Celgene, (5) EMD Serono, (6) Genzyme, (7) Hoffmann-La Roche, (8) Immunic, (9) Janssen Pharmaceuticals, (10) Medday, (11) Merck, (12) Mylan, (13) Nervgen, (14) Novartis, (15) Sanofi-Genzyme, (16) Teva Pharmaceutical, (17) TG Therapeutics, (18) Excemed, (19) MSIF and (20) NMSS.
Member of
NONE
NONE
NONE
(1) Biogen, (2) Celgene, (3) Merck, (4) Novartis, (5) Roche, (6) Sanofi-Genzyme and (7) Teva Pharmaceutical.
NONE
NONE
NONE
NONE
NONE
NONE
(1) Vice-president, Multiple Sclerosis Foundation of Barcelona (FEM) and (2) Vice-president, Fundació Cemcat
NONE
NONE
NONE
NONE
NONE
NONE
- Finn Sellebjerg, MD, PhD (sellebjerg{at}dadlnet.dk) and
Participation in advisory boards for Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi Genzyme.
NONE
Travel grants or speaker honoraria from Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva.
Section editor (immunology) for Multiple Sclerosis and Related Disorders since 2012
NONE
NONE
NONE
Member of steering committee for clinical trials for Merck and Roche. Consulting work for Novartis.
NONE
NONE
NONE
Research support from Biogen, Merck, Novartis, Roche, Sanofi Genzyme.
NONE
NONE
Grant support from: Danish Multiple Sclerosis Society, the Johnsen Foundation, Foundation for Research in Neurology, the Friis Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Shohreh Issazadeh-Navikas, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The Lundbeck Foundation, Danish Multiple Sclerosis Society, Foundation for Research in Neurology. Belinda Carrion received a PhD fellowship from CONACYT- Mexico and the Lundbeck Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) – Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) – Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark.
- Correspondence
Dr. Issazadeh-Navikas shohreh.issazadeh{at}bric.ku.dk
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
NK cell markers predict the efficacy of IV immunoglobulins in CIDPAnne K. Mausberg, Maximilian K. Heininger, Gerd Meyer Zu Horste et al.Neurology: Neuroimmunology & Neuroinflammation, October 02, 2020 -
Article
T-Cell Specificity Influences Disease Heterogeneity in Multiple SclerosisCarolina Cruciani, Marco Puthenparampil, Paula Tomas-Ojer et al.Neurology: Neuroimmunology & Neuroinflammation, September 17, 2021 -
Article
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosisCatharina C. Gross, Diana Ahmetspahic, Tobias Ruck et al.Neurology: Neuroimmunology & Neuroinflammation, October 12, 2016 -
Article
Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitroYukio Takeshita, Birgit Obermeier, Anne C. Cotleur et al.Neurology: Neuroimmunology & Neuroinflammation, December 19, 2016